In recent decades molecular engineering methods have seen impressive advances enabling the design of therapeutic antibodies and derivatives that now represent the fastest growing class of biopharmaceuticals .
Acticor Biotech product, ACT017, is a high affinity humanized antibody fragment (Fab) directed against a new therapeutic target of major interest: the platelet glycoprotein VI (GPVI). ACT017 is produced in CHO cells using the GPEx technology (Catalent).
ACT017 activity has been demonstrated in transgenic mice expressing the human GPVI and in primates. The results shown an inhibition of the collagen-induced platelet aggregation with no influence on bleeding time nor platelet count. The treatment will be a new option in the therapeutic landscape of stroke: it should be suitable for use in all patients, including those eligible to thrombolysis or not and patients beneficing of mechanical thrombectomy.